Loading…
Ocular Therapeutix, Inc. is projected to rise to $9.83 by 2027, a +16% move from its current price of $8.47. OCUL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $8.26 | $8.47 | $8.69 | +0.01% |
| Aug 2 | $8.17 | $8.47 | $8.79 | +0.02% |
| Aug 3 | $8.10 | $8.47 | $8.86 | +0.03% |
| Aug 4 | $8.05 | $8.47 | $8.92 | +0.04% |
| Aug 5 | $8.00 | $8.47 | $8.98 | +0.06% |
| Aug 6 | $7.96 | $8.48 | $9.03 | +0.07% |
| Aug 7 | $7.92 | $8.48 | $9.07 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.92 | $8.48 | $9.07 | +0.08% |
| Week 2 | $7.71 | $8.48 | $9.34 | +0.15% |
| Week 3 | $7.55 | $8.49 | $9.55 | +0.23% |
| Week 4 | $7.42 | $8.50 | $9.73 | +0.31% |
| Week 5 | $7.30 | $8.50 | $9.90 | +0.39% |
| Week 6 | $7.21 | $8.51 | $10.05 | +0.46% |
| Week 7 | $7.12 | $8.52 | $10.19 | +0.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ocular Therapeutix, Inc. is a healthcare company in the biopharmaceutical sector that develops and commercializes therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc.
was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL is a healthcare stock trading at $8.51 per share, with a market cap of $1.86B and a rank of 1953. The current price reflects a healthcare equity focusing on eye therapies. The near-term forecast for 2026 shows min $6.88, avg $8.51, max $11.20, with ROI 0 and sentiment NEUTRAL, indicating limited upside in the very near term.
In the longer run, forecasts point to upside with higher averages and ROIs into 2030 and beyond, including 2030 avg $12.69 and max $18.67 (ROI 49.2) and a 2050 max of $119.73 (ROI 645) with bullish sentiment.
A major floor 18.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 24.4% above — a clean break opens room to run.
A major ceiling 33.5% above — clearing it would confirm fresh momentum.
Key OCUL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OCUL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.49 | Sell | $8.51 | Sell |
| MA 10 | $8.62 | Sell | $8.71 | Sell |
| MA 20 | $9.28 | Sell | $8.99 | Sell |
| MA 50 | $9.09 | Sell | $9.16 | Sell |
| MA 100 | $9.02 | Sell | $9.32 | Sell |
| MA 200 | $10.12 | Sell | $9.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.23 | Neutral |
| Stoch RSI (14) | 12.64 | Buy |
| CCI (20) | -80.92 | Neutral |
| Williams %R (14) | -93.12 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -12.68 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 6.88 | Buy |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.90 | Sell |
| Ultimate (7,14,28) | 28.44 | Buy |
| Momentum (10) | -0.69 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 8.38 | Buy |
| ADX (14) | 18.86 | Neutral |
| ATR (14) | 0.22 | Info |
The 30-day technical picture is bearish with RSI(14) at 40. The stock trades below the SMA50 of $9.15 and the SMA200 of $10.20, signaling near-term weakness. Support is at $8.59 and resistance at $10.54, framing a near-term range roughly from $7.03 to $10.29 over the last 30 days. Annualized volatility is 60, indicating elevated price movement in the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.88 | $8.47 | $11.06 | 0% | Neutral | |
| $7.89 | $9.83 | $12.94 | +16% | Neutral | |
| $7.83 | $10.02 | $13.66 | +18% | Neutral | |
| $8.40 | $11.00 | $15.42 | +30% | Bullish | |
| $9.73 | $12.97 | $18.62 | +53% | Bullish | |
| $11.39 | $15.46 | $22.64 | +82% | Bullish | |
| $12.75 | $17.59 | $26.24 | +108% | Bullish | |
| $12.62 | $17.67 | $26.79 | +109% | Bullish | |
| $12.98 | $18.44 | $28.39 | +118% | Bullish | |
| $14.40 | $20.74 | $32.39 | +145% | Bullish | |
| $19.87 | $30.44 | $50.44 | +259% | Bullish | |
| $38.64 | $65.81 | $118.89 | +677% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.88 | $8.47 | $9.88 | +0.00% |
| August 2026 | $7.37 | $8.64 | $10.36 | +2.02% |
| September 2026 | $7.24 | $8.56 | $10.38 | -0.99% |
| October 2026 | $7.09 | $8.43 | $10.33 | -1.51% |
| November 2026 | $7.24 | $8.65 | $10.69 | +2.71% |
| December 2026 | $7.40 | $8.89 | $11.06 | +2.69% |
Click any year to see its month-by-month OCUL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, OCUL could reach as high as $11.06, with a base case around $8.47 and support toward $6.88 — roughly 0% from $8.47. Price action looks broadly range-bound.
Expect OCUL to range from $7.89 to $12.94 through 2027. The $9.83 average target implies a +16% move from current prices. That is up +16% on the projected 2026 average. A consolidation phase looks the most probable path here.
The OCUL price prediction for 2028 points to an average of $10.02 (low $7.83, high $13.66) — a potential gain of +18% on today's $8.47. Price action looks broadly range-bound.
In 2029, OCUL is projected to trade between $8.40 and $15.42, averaging $11.00 — a potential gain of +30% from today's $8.47. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Ocular Therapeutix, Inc.'s 2030 outlook centres on $12.97, within a $9.73 to $18.62 range. That is up +18% on the projected 2029 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2031, OCUL could reach as high as $22.64, with a base case around $15.46 and support toward $11.39 — roughly +82% from $8.47. Buyers look set to stay in control over this stretch.
Expect OCUL to range from $12.75 to $26.24 through 2032. The $17.59 average target implies a +108% move from current prices. That is up +14% on the projected 2031 average. Momentum favours further upside here.
The OCUL price prediction for 2033 points to an average of $17.67 (low $12.62, high $26.79) — a potential gain of +109% on today's $8.47. Buyers look set to stay in control over this stretch.
In 2034, OCUL is projected to trade between $12.98 and $28.39, averaging $18.44 — a potential gain of +118% from today's $8.47. That is up +4% on the projected 2033 average. Momentum favours further upside here.
Ocular Therapeutix, Inc.'s 2035 outlook centres on $20.74, within a $14.40 to $32.39 range. That is up +12% on the projected 2034 average. That marks a +145% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, OCUL could reach as high as $50.44, with a base case around $30.44 and support toward $19.87 — roughly +259% from $8.47. Momentum favours further upside here.
Expect OCUL to range from $38.64 to $118.89 through 2050. The $65.81 average target implies a +677% move from current prices. That is up +116% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in OCUL today (≈ 118.063754 OCUL) could be worth
$7,770.01
+$6,770.01 (+677%) by 2050 · US Dollar
Based on the average projected OCUL price of $65.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OCULwould be worth at today's price.
$1,000 invested in OCUL on Jul 30, 2025 (≈ 85.763294 OCUL) would be worth
$726.42
-$273.58 (-27.4%) today · 0.73× · US Dollar
Based on a OCUL entry price of $11.66 vs. today's $8.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.62 | $982.6 | -1.7% |
| 1 month ago | $9.82 | $862.53 | -13.7% |
| 3 months ago | $9.43 | $898.2 | -10.2% |
| 6 months ago | $9.14 | $926.7 | -7.3% |
| 1 year ago | $11.66 | $726.42 | -27.4% |
| All time (5.0y) ago | $11.26 | $752.22 | -24.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OCUL forecast.
Our base-case forecast reaches $17.00 around 2032.
Implied market cap at $17.00: $3.72B
Looking further out, the forecast shows bullish momentum from 2029 onward. In 2029 the avg price is $10.67 with a max of $15.29 and a min of $8.00, a ROI of 25.4 and bullish sentiment. By 2030 the avg price is $12.69 with a max of $18.67 and a min of $9.31, a ROI of 49.2 and bullish sentiment.
The trend continues through 2040 with an avg of $29.32, a max of $50.46, and a min of $18.31 (ROI 244.7) and by 2050 an avg of $63.36, a max of $119.73, and a min of $34.89 (ROI 645), all with bullish sentiment. These figures point to substantial upside potential but remain subject to execution risk and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows min $9.31, avg $12.69, max $18.67, with a ROI of 49.2 and bullish sentiment.
Forecasts indicate a bullish trend from 2029 onward, with 2030 avg $12.69 and 2050 avg $63.36, corresponding to ROI 49.2 in 2030 and ROI 645 in 2050, though near-term outlook remains neutral and risks exist.
The max forecast for 2050 is $119.73, with an avg of $63.36 and a min of $34.89, indicating that a price above $100 is possible in the max scenario for 2050, but it is not guaranteed.
Current price is $8.51 and market cap is $1.86B.
The 2026 forecast shows min $6.88, avg $8.51, max $11.20, ROI 0, sentiment NEUTRAL.
Ocular Therapeutix, Inc. Community Discussion
0Share your Ocular Therapeutix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.